Skip to product information

UCLA 16th Annual UCLA Liver Diseases Symposium 2023

UCLA 16th Annual UCLA Liver Diseases Symposium 2023

Regular price $30.00 USD
Regular price $30.00 USD Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
UCLA 16th Annual UCLA Liver Diseases Symposium 2023

UCLA 16th Annual UCLA Liver Diseases Symposium 2023

Regular price $30.00
Regular price $30.00 Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    UCLA 16th Annual UCLA Liver Diseases Symposium 2023

     

    • Include: 9 videos + 9 pdfs, size: 3.1 GB
    •  Target Audience: hepatologists, radiologists and surgeons

     Information:

    The 16th Annual UCLA Liver Diseases Symposium will provide a state-of-the-art update and scientific exchange on prevalent liver diseases and their complications using a multi-disciplinary approach with hepatologists, radiologists and surgeons.

    TARGET AUDIENCE

    Hepatologists, Radiologists, Surgeons, Nurses, Allied Healthcare Professionals, Fellows, and Residents.

    LEARNING OBJECTIVES

    At the conclusion of this program, participants will be able to:

    • Diagnose and develop a treatment strategy for acute kidney injury in patients with cirrhosis.
    • Identify indications and evaluation for liver transplantation, as well as the role of MELD in organ allocation.
    • Review the pros and cons of Transjugular Intrahepatic Portosystemic Shunts (TIPS) in patients with cirrhosis and portal hypertension, including expanding indications.
    • Implement new and novel strategies for the treatment of hepatocellular carcinoma (HCC).
    • Discuss specific liver disorders and injuries in women, as well as pregnancy hepatic complications.
    • Treat non-alcoholic fatty liver disease and be able to employ noninvasive tests for diagnosis and risk stratification.
    • Review the treatment of alcohol hepatitis, including long-term follow up, and understand controversies associated with early liver transplantation.
    • Discuss updates in the management of patients with viral hepatitis B, including those immunotolerant, and considerations for stopping antiviral therapy.
    • Diagnose acute liver failure, and risk stratify patients according to available laboratory results and clinical parameters.

     

     Topics:

    • Bronchure.pdf
    • Current Evaluation and Treatment of NASH.mp4
    • Current Evaluation and Treatment of NASH.pdf
    • Debate Treating Patients in the Hepatitis B Gray Zone and Stopping Hepatitis B Therapy.mp4
    • Debate Treating Patients in the Hepatitis B Gray Zone and Stopping Hepatitis B Therapy.pdf
    • Evaluation, Listing and Allocation in Liver Transplantation.mp4
    • Increasing Role of TIPS in the Management of Patients with Cirrhosis.mp4
    • Increasing Role of TIPS in the Management of Patients with Cirrhosis.pdf
    • Liver Diseases in Women, Including those who are Pregnant.mp4
    • Liver Diseases in Women, Including those who are Pregnant.pdf
    • Long Term Care of Patients with Alcohol Liver Disease including those with Alcohol Hepatitis.mp4
    • Long Term Care of Patients with Alcohol Liver Disease including those with Alcohol Hepatitis.pdf
    • Panel Case Discussion Acute Liver Failure.mp4
    • Panel Case Discussion Acute Liver Failure.pdf
    • Panel Case Discussion Multi-disciplinary Approach to Liver Cancer.mp4
    • Panel Case Discussion Multi-disciplinary Approach to Liver Cancer.pdf
    • Update on Treatment of Acute Kidney Injury in Patients with Cirrhosis.mp4
    • Update on Treatment of Acute Kidney Injury in Patients with Cirrhosis.pdf